Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3863 - Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma


10 Sep 2017


Poster display session


Translational Research;  Renal Cell Cancer


Ronan Flippot


Annals of Oncology (2017) 28 (suppl_5): v295-v329. 10.1093/annonc/mdx371


R. Flippot1, R. Mouawad1, J. Spano1, M. Rouprêt2, E. Compérat3, M. Bitker2, J. Parra2, C. Vaessen2, F. Allanic1, Q. Manach2, N. Tannir4, D. Khayat1, X. Su5, G. Malouf1

Author affiliations

  • 1 Medical Oncology, Groupe Hospitalier Pitié Salpetriere, 75651 - Paris/FR
  • 2 Urology, Pitié-Salpêtrière Hospital, 75651 - Paris/FR
  • 3 Pathology, Tenon Hospital, 75020 - Paris/FR
  • 4 Genitourinary Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 5 Biostatistics And Computational Biology, MD Anderson Cancer Center, 77030-4095 - Houston/US


Abstract 3863


Improved patient stratification is a challenge in adjuvant clear-cell renal cell carcinoma (ccRCC) trials. Long non-coding RNAs (lncRNAs) are genome-wide regulators with potent prognostic value. We aimed to predict risk of ccRCC recurrence based on lncRNA expression from two independent cohorts.


Identification of prognostic lncRNAs was performed in a training set of 351 samples of localized ccRCC from the Cancer Genome Atlas, using Cox regression based on disease-free (DFS) and overall survival. Functional annotation of differentially expressed genes according to lncRNA expression was performed. The validation cohort included 167 localized ccRCC patients. Gene expression was studied by qRT-PCR. Kaplan-Meier estimators and Cox regression models were used for survival and multivariate analyses. Primary endpoint was DFS.


MFI2-AS1 was best candidate lncRNA in the developmental study. Its expression was associated with immune response genes expression. In the validation cohort, MFI2-AS1 expression was associated with shorter DFS (Hazard Ratio (HR) for relapse 3·5, p = 0·0001), independently from Leibovich recurrence classification and grade. Combined with Leibovich classification, MFI2-AS1 status improved prediction of recurrence, with a C-index of 0·70 compared to 0·67 for MFI2-AS1 alone and 0·66 for Leibovich classification alone. In patients with aggressive tumors (Leibovich ≥ 5), MFI2-AS1 expression was associated with a dramatically increased risk or relapse (HR 12·16, p 


MFI2-AS1 is a potent predictor of recurrence in localized ccRCC. Combined with historical classifications, it provides a highly accurate patient stratification that may be useful in adjuvant settings.

Clinical trial identification

Legal entity responsible for the study

Gabriel G Malouf, MD, PhD. Fondation Avec & Hôpital Salpêtrière, Department of Medical Oncology, Paris, France


Fondation Avec


N. Tannir: Honoraria and consulting: Bristol-Myers Squib, Exelixis, Nektar, Novartis, Pfizer, Argos, Calithera. Research funding: Bristol-Myers Squib, Exelixis, Epizyme, Novartis, Miranti. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.